← Back to Search

OKN-007 + Temozolomide for Glioblastoma

Phase 1
Waitlist Available
Led By James Battiste, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
ECOG performance status within 0 - 2
Full recovery (< grade 1) from the adverse events associated with prior surgery or any earlier intervention and a minimum of 28 days from the administration of any investigational agent
Must not have
Second primary malignancy (except adequately treated basal cell carcinoma of the skin)
Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing if adding the drug OKN-007 to the standard treatment with Temozolomide and radiotherapy can help patients with malignant Glioblastoma, especially those whose cancer has gotten worse after initial treatment. Temozolomide has become a cornerstone in the treatment of glioblastoma, often used in combination with radiotherapy.

Who is the study for?
Adults with newly diagnosed Glioblastoma who've had surgery can join this trial. They need to provide tumor tissue, have a performance status of 0-2, and good organ function. Men must use contraception and not donate sperm for 120 days post-treatment. Women of childbearing potential must test negative for pregnancy and use birth control.
What is being tested?
The study tests OKN-007 combined with Temozolomide chemotherapy alongside standard radiotherapy in patients with Glioblastoma to see if it improves outcomes after initial treatment failure.
What are the potential side effects?
Potential side effects may include those typical of chemoradiotherapy such as fatigue, nausea, hair loss, skin irritation from radiation, low blood cell counts increasing infection risk, liver or kidney function changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
I have fully recovered from any side effects of previous treatments or surgeries.
Select...
My blood tests show normal kidney, liver, and bone marrow function.
Select...
I can provide at least five tissue samples from my brain tumor surgery for testing.
Select...
I am 18 years old or older.
Select...
I have been recently diagnosed with a high-grade brain tumor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have no other cancers except for treated skin cancer.
Select...
I haven't taken any unapproved drugs in the last 28 days.
Select...
My blood tests show high levels of sodium, potassium, or creatinine.
Select...
I am not pregnant or breastfeeding.
Select...
My kidneys are not working well (creatinine clearance < 60 mL/min).

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The maximum tolerated dose and the type of dose limiting toxicities
Secondary study objectives
Number of participants who are able to receive a reduction in steroid dose
Number of participants who comply with study treatment plan
Number of participants who experience overall survival
+1 more

Side effects data

From 2016 Phase 2 trial • 175 Patients • NCT01055314
36%
Febrile neutropenia
31%
Death NOS
30%
Diarrhea
22%
Pain
21%
Hyperglycemia
16%
Anorexia
16%
Infections and infestations - Other, specify
16%
Alanine aminotransferase increased
14%
Hypokalemia
13%
Nausea
11%
Hyponatremia
10%
Weight loss
9%
Aspartate aminotransferase increased
9%
Mucositis oral
9%
Anemia
9%
Vomiting
9%
Constipation
9%
Dehydration
9%
Hypophosphatemia
8%
Platelet count decreased
8%
Sepsis
7%
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
7%
Catheter related infection
7%
Colitis
7%
Abdominal pain
6%
Hypotension
6%
White blood cell decreased
6%
GGT increased
6%
Hypocalcemia
6%
Urinary retention
6%
Hypoalbuminemia
6%
Fever
5%
Typhlitis
5%
Anxiety
5%
Neutrophil count decreased
5%
Urinary tract infection
4%
Peripheral motor neuropathy
4%
Enterocolitis
4%
Lipase increased
4%
Pleural effusion
4%
Serum amylase increased
4%
Skin infection
4%
Epistaxis
4%
Urinary tract obstruction
3%
Blood bilirubin increased
3%
Lymphocyte count decreased
3%
Syncope
3%
Wound infection
3%
Dermatitis radiation
3%
Hypertension
3%
Sinus tachycardia
3%
Edema limbs
3%
Bone pain
3%
Dyspnea
3%
Hematuria
3%
Hypercalcemia
2%
Vulval infection
2%
Upper gastrointestinal hemorrhage
2%
Thromboembolic event
2%
Depressed level of consciousness
2%
Stridor
2%
Allergic reaction
2%
Back pain
2%
Lung infection
2%
Urticaria
2%
Acute kidney injury
2%
Muscle weakness lower limb
2%
Musculoskeletal and connective tissue disorder - Other, specify
2%
Pain in extremity
2%
Peripheral sensory neuropathy
2%
Proctitis
2%
Skin ulceration
2%
Apnea
2%
Stoma site infection
2%
Tumor pain
2%
Left ventricular systolic dysfunction
2%
Pancreatitis
2%
Portal hypertension
2%
Rectal hemorrhage
2%
Creatinine increased
2%
Enterocolitis infectious
2%
Hyperkalemia
2%
Investigations - Other, specify
2%
Abdominal distension
1%
Heart failure
1%
Ascites
1%
Vascular disorders - Other, specify
1%
Anal hemorrhage
1%
Penile pain
1%
Vasovagal reaction
1%
Gastrointestinal disorders - Other, specify
1%
Soft tissue infection
1%
Delirium
1%
Tracheitis
1%
Hepatobiliary disorders - Other, specify
1%
Seizure
1%
Esophageal pain
1%
Anal mucositis
1%
Menorrhagia
1%
Sore throat
1%
Bone marrow hypocellular
1%
Anaphylaxis
1%
Fracture
1%
Hydrocephalus
1%
Device related infection
1%
Tooth infection
1%
Gastric ulcer
1%
Sinusitis
1%
Skin and subcutaneous tissue disorders - Other, specify
1%
Pharyngitis
1%
Pyramidal tract syndrome
1%
Anal ulcer
1%
Depression
1%
Ejection fraction decreased
1%
Rash maculo-papular
1%
Pruritus
1%
Myositis
1%
Nail infection
1%
Pain of skin
1%
Pleuritic pain
1%
Pneumonitis
1%
Pneumothorax
1%
Postoperative hemorrhage
1%
Renal and urinary disorders - Other, specify
1%
Respiratory, thoracic and mediastinal disorders - Other, specify
1%
Salivary duct inflammation
1%
Small intestine infection
1%
Alkaline phosphatase increased
1%
Appendicitis
1%
Spinal fracture
1%
Disseminated intravascular coagulation
1%
Ear and labyrinth disorders - Other, specify
1%
Endocrine disorders - Other, specify
1%
Esophageal stenosis
1%
Esophagitis
1%
Gastric hemorrhage
1%
Gum infection
1%
Tumor lysis syndrome
1%
Upper respiratory infection
1%
Hypertriglyceridemia
1%
Hypoxia
1%
Ileus
1%
INR increased
1%
Laryngeal edema
1%
Multi-organ failure
1%
Myelodysplastic syndrome
1%
Oral hemorrhage
1%
Oral pain
1%
Pulmonary edema
1%
Rectal fistula
1%
Rectal pain
1%
Respiratory failure
1%
Bladder spasm
1%
Chest wall pain
1%
Confusion
1%
Congenital, familial and genetic disorders - Other, specify
1%
CPK increased
1%
Dizziness
1%
Encephalopathy
1%
Eye disorders - Other, specify
1%
Generalized muscle weakness
1%
Hoarseness
1%
Hypernatremia
1%
Hypoglycemia
1%
Hypomagnesemia
1%
Insomnia
1%
Irregular menstruation
1%
Irritability
1%
Joint range of motion decreased cervical spine
1%
Kyphosis
1%
Lethargy
1%
Headache
1%
Laryngeal mucositis
1%
Pelvic pain
1%
Esophageal infection
1%
Abdominal infection
1%
Acidosis
1%
Anal fistula
1%
Fall
1%
Fatigue
1%
Gait disturbance
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group 1 (Chemotherapy, Radiation Therapy, Cixutumumab)
Group 2 (Chemotherapy, Radiation Therapy, Temozolomide)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: OKN-007 5 days per week and temozolomideExperimental Treatment3 Interventions
OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
Group II: OKN-007 3 days per week plus temozolomideExperimental Treatment3 Interventions
OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Temozolomide
2010
Completed Phase 3
~1880

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Temozolomide, a common treatment for Glioblastoma, works by alkylating/methylating DNA, leading to tumor cell death by disrupting DNA replication and repair. OKN-007, currently under investigation, is believed to exert anti-angiogenic, anti-inflammatory, or cytotoxic effects, which can inhibit tumor growth and reduce inflammation. These mechanisms are important for Glioblastoma patients as they provide targeted approaches to disrupt tumor growth and improve treatment outcomes.

Find a Location

Who is running the clinical trial?

University of OklahomaLead Sponsor
474 Previous Clinical Trials
93,664 Total Patients Enrolled
3 Trials studying Glioblastoma
65 Patients Enrolled for Glioblastoma
James Battiste, MDPrincipal InvestigatorPrincipal Investigator
1 Previous Clinical Trials
15 Total Patients Enrolled
1 Trials studying Glioblastoma
15 Patients Enrolled for Glioblastoma

Media Library

Photon/Proton IMRT Clinical Trial Eligibility Overview. Trial Name: NCT03587038 — Phase 1
Glioblastoma Research Study Groups: OKN-007 3 days per week plus temozolomide, OKN-007 5 days per week and temozolomide
Glioblastoma Clinical Trial 2023: Photon/Proton IMRT Highlights & Side Effects. Trial Name: NCT03587038 — Phase 1
Photon/Proton IMRT 2023 Treatment Timeline for Medical Study. Trial Name: NCT03587038 — Phase 1
~4 spots leftby Dec 2025